

Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK

ZHENFENG HAO¹, JING QIAN¹ and JISHI YANG²

¹Laboratory of Traditional Chinese Medicines, Medical College of Yangzhou University, Yangzhou, Jiangsu 225001;

²Department of Gynecology and Obstetrics, The Affiliated Taixing Hospital,
Yangzhou University, Yangzhou, Jiangsu 225004, P.R. China

Received April 16, 2014; Accepted November 21, 2014

DOI: 10.3892/ol.2014.2771

Abstract. The present study identified that shikonin, a naphthoquinone extracted from the roots of *Lithospermum erythrorhizon*, inhibits the migration of ovarian cancer cells and induces their apoptosis by impairing the phosphorylation of two kinases, proto-oncogene tyrosine protein kinase Src (Src) and focal adhesion kinase (FAK). Ovarian carcinoma SKOV-3 cells were treated with various concentrations of shikonin and analyzed for the effects on cell migration, invasion and apoptosis via Transwell assays and flow cytometry. In addition, the effects of shikonin administration on the expression and phosphorylation of Src and FAK in the SKOV-3 cells were analyzed by western blotting. Shikonin appeared to induce apoptosis and decrease cell migration in the SKOV-3 ovarian cells. Furthermore, the present study provides evidence that shikonin may exert these effects on human ovarian carcinoma cells via the inhibition of the protein tyrosine kinases, Src and FAK. Thus, shikonin should be considered for additional investigation as a candidate agent for the prevention and treatment of human ovarian cancer.

Introduction

Shikonin, a naphthoquinone extracted from the roots of *Lithospermum erythrorhizon*, is a potent antioxidant with anti-inflammatory, antiviral and cancer-preventing properties (1). Shikonin exhibits significant cytotoxic activity against

multiple cancer cell types *in vitro* and *in vivo* (2,3), and a number of studies have previously established a potential role for shikonin as a candidate therapeutic agent in the treatment of cancer (4,5). However, the mechanism by which shikonin achieves this effect has yet to be fully elucidated (6).

Ovarian carcinoma is the most lethal type of gynecological malignancy. The response to traditional platinum-based chemotherapy is poor in numerous patients, therefore, current research is focused on the development of novel therapeutic strategies. Protein tyrosine kinases (PTKs) are important in cellular signal transduction pathways and regulate numerous cellular activities, including cell growth, migration, differentiation and apoptosis (7,8). Furthermore, the abnormal activation of PTKs is closely associated with ovarian carcinoma (8), therefore, PTKs are attractive targets for anticancer agents.

The expression and activity of the proto-oncogene tyrosine kinase Src (Src) is associated with a poor prognosis and advanced malignancy in a range of types of human cancer, including ovarian carcinoma (9,10). Focal adhesion kinase (FAK), an intracellular PTK recruited to focal adhesion sites, acts via cell surface receptors as a major mediator of signal transduction (11). FAK has been demonstrated to be key factor in the regulation of cell survival (12), proliferation, differentiation, migration, invasion (13) and angiogenesis (14), all of which are vital processes in the development of cancer. Furthermore, FAK is overexpressed in ovarian cancer (15). Therefore, FAK may be involved in promoting tumorigenesis and metastasis in cancer.

In the present study, it was hypothesized that shikonin may have a role as an inhibitor of ovarian cancer cells growth and migration, and therefore, could potentially serve as a therapeutic agent for the management of human ovarian cancers.

Materials and methods

Preparation of shikonin. Shikonin was purchased from ChromaDex, Inc., (cat. no., ASB-00019210-005; Irvine, CA, USA), dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA) and stored at -20°C. For all experiments in the present study, the final concentrations of the compounds analyzed were prepared by diluting the stock solution with culture medium, while the control cultures were diluted with the carrier solvent (0.1% DMSO).

Correspondence to: Dr Jing Qian, Laboratory of Traditional Medicines, Medical College of Yangzhou University, 11 Huaihai Road, Yangzhou, Jiangsu 225001, P.R. China
E-mail: yzqj2000@163.com

Dr Jishi Yang, Department of Gynecology and Obstetrics, The Affiliated Taixing Hospital, Yangzhou University, 1 Changzheng Road, Yangzhou, Jiangsu 225004, P.R. China
E-mail: zhenfenghaoyl@126.com

Key words: shikonin, ovarian cancer, apoptosis, Src, focal adhesion kinase, phosphorylation

Cell culture. SKOV-3 cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in a monolayer culture at 37°C and 5% CO₂ in McCoy's 5A medium (Gibco Life Technologies, Carlsbad, CA, USA) with 10% fetal bovine serum (Gibco Life Technologies).

Cytotoxicity assay. The cytotoxic effect of shikonin on the SKOV-3 cells was measured by performing a Cell Counting kit (CCK)-8 assay (Dojindo Laboratories, Kumamoto, Japan). Briefly, the cells were dispensed into a 96-well flat-bottomed microtiter plate (Thermo Scientific Nunc, Roskilde, Denmark) at a density of 1×10^4 cells/well, followed by treatment with various concentrations of shikonin (1, 2, 4, 8, 16, 32, 64, 128 or 256 μ M) for 48 h. Cell growth was measured using an enzyme-linked immunosorbent assay reader (Tecan Spectra, Wetzlar, Germany) to analyze the CCK-8 assay.

Flow cytometric analysis. The rate of apoptosis was measured using an Annexin V-fluorescein isothiocyanate/propidium iodide (FITC/PI) apoptosis detection kit (Invitrogen Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. The cells were exposed to various concentrations of shikonin (0, 4, 8 and 16 mmol/l), incubated for 48 h, collected and washed twice with phosphate-buffered saline (PBS). Next, the cells were gently resuspended in Annexin V binding buffer, incubated with Annexin V-FITC/PI in the dark for 15 min and analyzed using flow cytometry.

Caspase activity assay. The SKOV-3 cells (1×10^6) were incubated without or with shikonin (16 μ M). The cells were harvested at 0, 12, 24, 48 and 72 h, washed with PBS and pelleted. The supernatant was aspirated, cell lysis buffer was added at 0.5 ml/ 1×10^6 cells and then the cells in the lysis buffer were incubated on ice for 10 min. Reaction buffer containing 5 μ l dithiothreitol, 5 μ l DEVD-AFC amino acid substrate and 380 μ l H₂O was added to each aliquot of cell lysate and the mixtures were incubated at 37°C for 1 h. The fluorescence emitted by the cleaved substrates was determined using a spectrofluorometer at an absorbance of 400 nm for excitation and 505 nm for emission. One unit of enzyme activity corresponds to the activity required to cleave 1 mg of substrate in 1 min at 37°C.

Migration assay. The SKOV-3 cells were plated onto the upper membrane of a Transwell unit (8- μ m pore size; Merck Millipore, Darmstadt, Germany) at a density of 4×10^5 cells/well. The cells were exposed to various concentrations of shikonin (0, 4, 8 and 16 μ mol/l) and incubated for 24 h. Any non-migrated cells on the upper membrane were removed using a cotton swab, while the migrated cells (located on the lower surface of the Transwell filters) were fixed for 5 min in methanol, stained with 0.1% crystal violet, eluted with 33% ethylic acid and measured at an absorbance of 480 nm to obtain the optical density values.

Western blot analysis. The SKOV-3 cells were harvested and lysed for 1 h on ice in lysis buffer [50 mM Tris-Cl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na₃VO₄, 1 mM NaF, mammalian protease inhibitor cocktail and phosphatase inhibitor cocktail; Roche Diagnostics, Indianapolis, IN, USA]. The




Figure 1. Inhibitory effect of shikonin on the growth of SKOV-3 cells. IC₅₀, half maximal inhibitory concentration.

caspase protein concentrations were determined by performing a bicinchoninic acid assay. The lysate was centrifuged at 16,000 \times g and 4°C for 10 min, and then equal quantities of total protein were mixed with loading buffer, boiled for 5 min and subjected to electrophoresis on a 10% SDS-polyacrylamide gel. Subsequently, the proteins were electrotransferred onto polyvinylidene difluoride membranes. Subsequent to blocking with Tris-buffered saline (TBS) containing 5% skimmed milk at room temperature, the membranes were incubated for 2 h at room temperature with polyclonal rabbit anti-human caspase-3, -8 and -9 (1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) primary antibodies in TBS. Following three 10-min washes in TBS, the membranes were incubated with a diluted horseradish peroxidase-labeled secondary antibody for 1 h and after an additional three washes, the protein expression levels were detected using an enhanced chemiluminescence kit, according to the manufacturer's instructions (Bio-Rad Laboratories, Hercules, CA, USA).

Statistical analysis. Data are presented as the mean \pm standard deviation of the results from three independent experiments. Differences were assessed by the two-tailed Student's t-test. Statistical analyses were performed using SPSS version 16.0 software (SPSS, Inc., Chicago, IL, USA). All graphs were obtained using Microsoft Office Excel 2010 software (Microsoft Research, Redmond, WA, USA). $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Inhibition of cell growth by shikonin. To determine the inhibitory effects of shikonin on the growth of cultured SKOV-3 cells and to ascertain the viability of SKOV-3 cells in the presence of shikonin, a CCK-8 assay was performed. Treating the SKOV-3 cells with increasing concentrations of shikonin identified 10.38 μ mol as the half maximal inhibitory concentration of shikonin (Fig. 1).

Shikonin induces the apoptosis of SKOV-3 cells. The SKOV-3 cells were treated with various concentrations of shikonin for 48 h (Fig. 2A) and the percentage of apoptotic cells present following treatment is indicated in Fig. 2B. Increasing concentrations of shikonin were associated with increased levels of SKOV-3 cell apoptosis.




Figure 2. Shikonin induces cell death in SKOV-3 cells. (A) SKOV-3 cells were treated with dimethyl sulfoxide (DMSO; control) or 0, 4, 8 or 16 μ M shikonin for 48 h, followed by use of an Annexin V-FITC binding assay. Cell death was measured by Annexin-V and PI staining, and flow cytometry; data are presented as cytograms. Viable cells were negative for Annexin-V and PI staining (lower left quadrant), early-stage apoptotic cells were positive for annexin-V staining, but negative for PI staining (lower right quadrant), and late-stage apoptotic cells were positive for Annexin-V and PI staining (upper right quadrant). (B) The percentage of Annexin V-stained cells following treatment with with DMSO (control) or 0, 4, 8 or 16 μ M shikonin. Data are presented as the mean \pm standard deviation (n=3). *P<0.05 vs. control group. FITC, fluorescein isothiocyanate; PI, propidium iodide.




Figure 3. Shikonin activates caspases-3, -8 and -9 in SKOV-3 cells. (A) Western blot analysis demonstrating the effect of treatment with various concentrations of shikonin (0, 4, 8 and 16 μ M) for 48 h on the expression of cleaved caspase-3, -8, and 9 (n=3). GAPDH was used as the internal control. (B) The activity of caspase-3 protease during shikonin-induced apoptosis (0, 12, 24, 48 and 72 h) following treatment with 16 μ M shikonin. Data are presented as the mean \pm standard deviation of three independent experiments.

Effect of shikonin on caspase activation. The changes in caspase-3, -8 and -9 protein expression levels in response to shikonin administration were determined by performing western blot analysis (Fig. 3A) and it was found that the levels of cleaved caspase-3, -8 and -9 were increased following treatment with shikonin for 48 h. The activity of

caspase-3 protease increased during shikonin-induced apoptosis (Fig. 3B)

Effect of shikonin on the motility and invasion of SKOV-3 cells. Treatment of the SKOV-3 cells with increasing concentrations of shikonin for 12 h resulted in a dose-dependent decrease in cell migration (Fig. 4A and B). Furthermore, the SKOV-3 cells that underwent longer treatment periods with shikonin (24 h) also exerted a dose-dependent inhibitory effect on cell invasion (Fig. 4C and D).

Effect of shikonin on the activity and protein expression levels of Src and FAK in SKOV-3 cells. The activity of Src and FAK in the SKOV-3 cells was measured by performing western blot analyses of Tyr-397-phosphorylated FAK and Tyr-416-phosphorylated Src. The activity of Src and FAK decreased in response to treatment with shikonin in a dose-dependent manner. Additionally, the expression of Src and FAK was decreased in the SKOV-3 cells in response to treatment with shikonin (Fig. 5). These results indicate that shikonin may be crucial in the down-regulation of FAK expression.

Discussion

Shikonin, a novel compound isolated from the Chinese herbal therapeutic agent Zicao, has been demonstrated to exhibit anticancer activity (16,17). Previous studies have indicated that shikonin inhibits tumor formation, carcinogenesis and metastasis, predominantly by inhibiting the proliferation and induction of apoptosis in tumor cell lines (18,19). Various molecular targets have been associated with shikonin-induced apoptotic cell death (20,21), however, the mechanism by which shikonin exhibits its anticancer activity is poorly understood.




Figure 4. Shikonin dosage effects on SKOV-3 cell migration and invasion. (A) SKOV-3 cells were treated with dimethyl sulfoxide (DMSO; control) or 0, 4, 8 or 16 μ M shikonin for 12 h, followed by a Transwell migration assay. (B) OD values of 33% ethylic acid eluent indicating the quantity of migrated cells. (C) SKOV-3 cells were treated with DMSO (control) or 0, 4, 8 or 16 μ M shikonin for 24 h, followed by use of a Transwell invasion assay. (D) OD values of 33% ethylic acid eluent indicating the quantity of invasive cells. OD, optical density.




Figure 5. Effect of Shikonin on the expression of FAK, Tyr-397 phospho-FAK, Src and Tyr-416 phospho-Src protein in SKOV-3 cells. Western blot analysis demonstrated inhibition of FAK and Src protein expression levels following treatment with dimethyl sulfoxide (control) or 0, 4, 8 or 16 μ M shikonin. FAK, focal adhesion kinase; Src, proto-oncogene tyrosine protein kinase Src.

In the present study, a potential therapeutic pathway was identified by which shikonin appears to target ovarian cancer cells by inhibiting growth and inducing apoptosis. Shikonin has previously been demonstrated to exhibit an inhibitory effect on human colorectal carcinoma COLO 205 cells via the induction of apoptotic cell death, accompanied by the upregulation of p27 and p53, and the downregulation of B-cell lymphoma (Bcl)-2 and Bcl-extra large (22). Furthermore, shikonin induces HeLa cell death via caspase-3 activation (23). Similarly, the

present study detected caspase activation in shikonin-induced ovarian cell apoptosis. Furthermore, the extrinsic death receptor pathway and the intrinsic mitochondrial pathway appears to be involved in shikonin-induced apoptosis, indicating that the two pathways may interact with and amplify each other in the process of activating effector caspases, such as caspase-3 (23).

Additionally, the present study identified that shikonin decreases ovarian cancer cell migration and invasion; this was demonstrated by the treatment of SKOV-3 cells with various concentrations of shikonin, causing a reduction in the motility of the ovarian cancer cells. A shikonin derivative, β -hydroxyisovalerylshikonin, inhibits the PTK activities of epidermal growth factor and viral-Src receptors (24). Src and Src-family PTKs are regulatory proteins that play key roles in cell differentiation, motility, proliferation and survival (25). Src protein inhibition occurs via targeting of its phosphorylation sites; the Src phosphorylation sites initially described include the autophosphorylated activation site at Tyr 416. In agreement with the aforementioned previous studies, the present study demonstrated that shikonin inhibits Src activity in SKOV-3 cells.

FAK, a non-receptor PTK, is a key component of focal adhesion sites, particularly in the promotion, spread, migration and transmission of anchorage-dependent anti-apoptotic signals (26). FAK is activated following the engagement of adjacent integrin molecules or the stimulation of transmembrane receptors (27,28); and this activation occurs via tyrosine autophosphorylation, as well as via phosphorylation by other PTKs, including Src family kinases (29,30) and the insulin receptor (31). Tyr-397 autophosphorylation is an important step for promoting the biological

function of FAK, and Tyr-576 and -577 phosphorylation by Src increases FAK activity (32). Previously, increased protein expression levels of FAK have been identified in various types of ovarian cancer, rendering FAK a potentially valuable target for therapeutic intervention (15). Furthermore, increased FAK expression and activity have previously been correlated with malignant or metastatic disease and poor patient prognosis (33). FAK is regulated by growth factor receptor stimulation and acts as a signaling intermediate that is recruited to focal adhesions immediately following integrin activation, therefore, the present study determined FAK activity in response to the presence of various concentrations of shikonin by analyzing the level of FAK autophosphorylation. In the SKOV-3 cells, shikonin decreased FAK activity in a dose-dependent manner. The present study additionally reported that shikonin appears to inhibit the metastasis of ovarian cancer cells; it is proposed that shikonin may mediate this metastatic effect by decreasing the activity and expression of FAK.

In conclusion, shikonin was shown to induce apoptosis and decrease cellular migration in ovarian cancer cells. In addition, shikonin decreased FAK activity in a dose-dependent manner. Therefore, shikonin requires consideration as a candidate agent for the prevention and treatment of human ovarian cancer.

Acknowledgements

This study was supported by the China National Science Foundation (grant no. 81272537) and the Jiangsu Traditional Chinese Medicine Science and Technology Project Foundation for 2013 (grant no. LZ13206).

References

- Ishida T and Sakaguchi I: Protection of human keratinocytes from UVB-induced inflammation using root extract of *Lithospermum erythrorhizon*. *Biol Pharm Bull* 30: 928-934, 2007.
- Yeh CC, Kuo HM, Li TM, *et al*: Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24). *In Vivo* 21: 1011-1019, 2007.
- Wu Z, Wu LJ, Tashiro S, *et al*: Phosphorylated extracellular signal-regulated kinase up-regulated p53 expression in shikonin-induced HeLa cell apoptosis. *Chin Med J (Engl)* 118: 671-677, 2005.
- Li W, Liu J, Jackson K, Shi R and Zhao Y: Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells. *PloS One* 9: e94079, 2014.
- Jang SY, Jang EH, Jeong SY and Kim JH: Shikonin inhibits the growth of human prostate cancer cells via modulation of the androgen receptor. *Int J Oncol* 44: 1455-1460, 2014.
- Wang W, Dai M, Zhu C, *et al*: Synthesis and biological activity of novel shikonin analogues. *Bioorg Med Chem Lett* 19: 735-737, 2009.
- Al-Obeidi FA and Lam KS: Development of inhibitors for protein tyrosine kinases. *Oncogene* 19: 5690-5701, 2000.
- Hunter T: Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. *Cell* 80: 225-236, 1995.
- Wheeler DL, Iida M and Dunn EF: The role of Src in solid tumors. *Oncologist* 14: 667-678, 2009.
- Wiener JR, Windham TC, Estrella VC, *et al*: Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. *Gynecol Oncol* 88: 73-79, 2003.
- Parsons JT: Focal adhesion kinase: the first ten years. *J Cell Sci* 116: 1409-1416, 2003.
- Westhoff MA, Serrels B, Fincham VJ, *et al*: SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. *Mol Cell Biol* 24: 8113-8133, 2004.
- Schlaepfer DD and Mitra SK: Multiple connections link FAK to cell motility and invasion. *Curr Opin Genet Dev* 14: 92-101, 2004.
- Peng X, Ueda H, Zhou H, *et al*: Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. *Cardiovasc Res* 64: 421-430, 2004.
- Judson PL, He X, Cance WG and Van Le L: Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. *Cancer* 86: 1551-1556, 1999.
- Sankawa U, Ebizuka Y, Miyazaki T, Isomura Y and Otsuka H: Antitumor activity of shikonin and its derivatives. *Chem Pharm Bull (Tokyo)* 25: 2392-2395, 1977.
- Sankawa U, Otsuka H, Kataoka Y, Iitaka Y, Hoshi A and Kureitani K: Antitumor activity of shikonin, alkannin and their derivatives. II. X-ray analysis of cyclo-alkannin leucoacetate, tautomerism of alkannin and cyclo-alkannin and antitumor activity of alkannin derivatives. *Chem Pharm Bull (Tokyo)* 29: 116-122, 1981.
- Yang H, Zhou P, Huang H, *et al*: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. *Int J Cancer* 124: 2450-2459, 2009.
- Lee HJ, Lee HJ, Magesh V, Nam D, *et al*: Shikonin, acetylshikonin and isobutyrylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice. *Yakugaku Zasshi* 128: 1681-1688, 2008.
- Wu Z, Wu L, Li L, Tashiro S, Onodera S and Ikejima T: p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. *J Pharmacol Sci* 94: 166-176, 2004.
- Han W, Li L, Qiu S, *et al*: Shikonin circumvents cancer drug resistance by induction of a necroptotic death. *Mol Cancer Ther* 6: 1641-1649, 2007.
- Hsu PC, Huang YT, Tsai ML, Wang YJ, Lin JK and Pan MH: Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27 and p53, release of cytochrome c and sequential activation of caspases in human colorectal carcinoma cells. *J Agric Food Chem* 52: 6330-6337, 2004.
- Wu Z, Wu LJ, Li LH, Tashiro S, Onodera S and Ikejima T: Shikonin regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis. *J Asian Nat Prod Res* 6: 155-166, 2004.
- Nakaya K and Miyasaka T: A shikonin derivative, beta-hydroxy-isovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. *Anticancer Drugs* 14: 683-693, 2003.
- Roskoski R Jr: Src kinase regulation by phosphorylation and dephosphorylation. *Biochem Biophys Res Commun* 331: 1-14, 2005.
- Schlaepfer DD and Hunter T: Integrin signalling and tyrosine phosphorylation: just the FAKs? *Trends Cell Biol* 8: 151-157, 1998.
- Hanks SK, Calalb MB, Harper MC and Patel SK: Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. *Proc Natl Acad Sci USA* 89: 8487-8491, 1992.
- Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB and Parsons JT: pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. *Proc Natl Acad Sci USA* 89: 5192-5196, 1992.
- Calalb MB, Polte TR and Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. *Mol Cell Biol* 15: 954-963, 1995.
- Cobb BS, Schaller MD, Leu TH and Parsons JT: Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. *Mol Cell Biol* 14: 147-155, 1994.
- Baron V, Calléja V, Ferrari P, Alengrin F and Van Obberghen E: p125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors. *J Biol Chem* 273: 7162-7168, 1998.
- Schlaepfer DD, Hanks SK, Hunter T and van der Geer P: Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. *Nature* 372: 786-791, 1994.
- Recher C, Ysebaert L, Beyne-Rauzy O, *et al*: Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity and poor prognosis. *Cancer Res* 64: 3191-3197, 2004.